Karl Gubitz

Karl Gubitz joined argenx as Chief Financial Officer in June 2021. Karl worked at Pfizer for nearly 20 years, most recently as Vice President of Finance within the Global Oncology business. During his tenure at Pfizer, he successfully negotiated the commercialization model for tanezumab with Eli Lilly in all non-US markets as well as the Myovant co-commercialization agreement for Orgovyx™.

Within Pfizer, Karl held country, regional, and global positions, and consistently delivered top-line growth. He managed teams of over 250 colleagues in financial leadership roles within the Global Internal Medicine and Global Innovative Products businesses. Prior to joining Pfizer in 2003, Karl held various management roles at PricewaterhouseCoopers.

He holds an M.B.A. from Henley Management College in the UK, Bachelor’s degree in computing from the University of South Africa, and Bachelor of Commerce from the University of Pretoria.